Quoin Pharmaceuticals, Ltd.
QNRX
$-0.08
Change (1 day)
$6.18
Year High
$0.43
Year Low
Categories
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
P/E ratio for Quoin Pharmaceuticals, Ltd. (QNRX)
P/E ratio as of 2023: -0.51
According to Quoin Pharmaceuticals, Ltd.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.51. At the end of 2022 the company had a P/E ratio of -0.74.
P/E ratio history for Quoin Pharmaceuticals, Ltd. from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.51 |
| 2022 | -0.74 |
| 2021 | -0.85 |
| 2020 | -14.71 |
| 2019 | -3.03 |
| 2018 | 0.89 |
| 2017 | 3.85 |
| 2016 | 0.92 |
| 2015 | -0.59 |